TFPT inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TFPT (Thrombin-Fibrinogen Proteinase Thrombin) protein, an enzyme involved in critical biological processes such as blood coagulation and wound healing. TFPT is responsible for converting fibrinogen into fibrin, which is essential for the formation of blood clots. These inhibitors function primarily by binding to key regions of the TFPT protein, such as its active site or the areas that interact with fibrinogen. By occupying these crucial binding sites, TFPT inhibitors effectively prevent the enzyme from performing its normal function, thereby disrupting the coagulation cascade. Additionally, some TFPT inhibitors may act through allosteric mechanisms, where they bind to sites on the enzyme that are distinct from the active site, inducing conformational changes that reduce the enzyme's catalytic activity. The interactions between TFPT inhibitors and the protein are typically stabilized by various non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions, ensuring effective inhibition.
Structurally, TFPT inhibitors exhibit considerable diversity, enabling them to selectively engage with various regions of the TFPT protein. These inhibitors often contain functional groups such as hydroxyl, carboxyl, or amine groups that facilitate strong interactions through hydrogen bonding and ionic interactions with critical amino acid residues within the protein's binding pockets. Many TFPT inhibitors also feature aromatic rings or heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the enzyme, further contributing to the stability and efficacy of the inhibitor-protein complex. The physicochemical properties of TFPT inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are meticulously optimized to ensure effective binding and stability across various biological environments. This balance between hydrophilic and hydrophobic characteristics allows TFPT inhibitors to selectively interact with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TFPT activity in diverse cellular contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
A BET bromodomain inhibitor, JQ1 can disrupt protein-protein interactions involving transcription factors and chromatin, potentially influencing TFPT-related pathways. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
Similar to JQ1, this compound inhibits BET bromodomain-containing proteins, impacting transcription regulation and possibly affecting TFPT activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
An HDAC inhibitor, Vorinostat alters chromatin structure and gene expression, potentially affecting TFPT-mediated transcriptional regulation. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
A potent HDAC inhibitor known to affect gene expression, possibly impacting TFPT's role in transcriptional regulation. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A DNA methyltransferase inhibitor, potentially disrupting transcriptional regulation processes in which TFPT is involved. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
An inhibitor of EZH2, a component of the Polycomb repressive complex 2 (PRC2), which might influence TFPT's role in gene repression. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
A non-nucleoside DNA methyltransferase inhibitor, which could indirectly affect TFPT's function in gene regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, known to affect various signaling pathways, which could indirectly influence TFPT's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, part of the MAPK/ERK pathway, potentially impacting TFPT indirectly through signaling pathways. | ||||||